Cargando…
A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men
BACKGROUND: A novel formulation of oral testosterone undecanoate (TU) was studied in a long- and short-term phase III trial to evaluate safety and efficacy. METHODS: Hypogonadal men (age 18–65 years; two morning serum testosterone (T) <300 ng/dl with signs/symptoms) were recruited into a 365 day...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328356/ https://www.ncbi.nlm.nih.gov/pubmed/32655691 http://dx.doi.org/10.1177/1756287220937232 |